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Purpose: The association of the metal chelating portion of thiosemicarbazone with the cytotoxic 21 
activity of sigma-2 receptors appears as a promising strategy in pancreatic tumors. Therefore, we 22 
developed a novel sigma-2 receptor targeting thiosemicarbazone (FA4) that incorporates a moiety 23 
associated with lysosome destabilization and ROS increase in order to develop more efficient 24 
antitumor agents. 25 
Methods: The density of sigma receptors was evaluated in pancreatic cells by flow cytometry 26 
analyses. In these cells, cytotoxicity (MTT assay) and the activation of the ER and mitochondria -27 
dependent (mRNA expression of GRP78, ATF6, IRE1, PERK; ROS levels by MitoSOX and 28 
DCFDA-AM; JC-1 staining) cell death pathways induced by thiosemicarbazones FA4, MLP44, PS3 29 
and ACthio-1, were evaluated. Autophagic proteins (ATG5, ATG7, ATG12, beclin, p62 and LC3-I) 30 
were also studied. In vivo effect of FA4 in xenografts was investigated and challenged with 31 
gemcitabine.  32 
Results: FA4 exerted more potent cytotoxicity than the previously studied thiosemicarbazones 33 
(MLP44, PS3 and ACthio-1) which displayed variable effects on the ER or mitochondria -dependent 34 
pro-apoptotic axis. By contrast, FA4 always activated pro-apoptotic pathways and decreased 35 
autophagy, except for MiaPaCa2 cells, where autophagy proteins were less expressed and unmodified 36 
by FA4. Treatment of PANC-1 mice models, poorly responsive to conventional chemotherapy, with 37 
FA4 significantly reduced tumor volume and increased intratumor apoptosis compared to 38 
gemcitabine, with no signs of toxicity. 39 
Conclusion: Altogether, FA4 that shows encouraging activity in cells unresponsive to gemcitabine, 40 
deserves further investigation in patient-derived pancreatic adenocarcinomas, while the results 41 
obtained held promises for the development of therapies that can more efficiently target the peculiar 42 




Keywords: Thiosemicarbazone, adenocarcinoma pancreatic tumor, sigma receptors, caspase 3/7/9, 45 
autophagy, PANC-1 xenograft. 46 
Introduction 47 
Pancreatic tumor is one of the most aggressive cancers characterized by a very poor prognosis and a 48 
five-years survival rate around 8%. While the overall cancer death rate has constantly declined over 49 
the past two decades for the four major cancers (lung, breast, prostate, and colorectum), death rates 50 
increased for pancreatic cancers. [1] Surgery represents the first option when the disease is early 51 
diagnosed, with gemcitabine as the chemotherapeutic agent towards which cancer cells ultimately 52 
develop resistance. Therefore, there is an urgent need for alternative therapeutic strategies to face 53 
such harmful disease. With this aim, we previously produced a series of thiosemicarbazones that 54 
chelate metals and display activity towards the sigma-2 receptors and the drug efflux pump P-55 
glycoprotein (P-gp). [2] The strategy to simultaneously hit these targets against pancreatic cancer was 56 
based on diverse pieces of evidence: 1) some sigma-2 receptor ligands are effective against pancreatic 57 
tumors [3–7]; 2) cancer cells are sensitive to changes in energy levels because of their increased 58 
energy need to support rapid cell proliferation. [8] Interaction with the subtype 2 of sigma receptors, 59 
that are overexpressed in several tumors, activates apoptotic pathways that depend on the cell type 60 
and on the molecule type. [9] Upon metal (iron and copper) chelation, thiosemicarbazones are able 61 
to alter the cell energy equilibrium. In the attempt to link these two activities, potent cytotoxic 62 
thiosemicarbazones that bind sigma-2 receptor were obtained and the impact to the synergistic action 63 
of the biological targets hit by these molecules (i.e sigma-2 receptors, efflux pumps like P-gp and 64 
metal chelation) was studied through a deconstruction approach (Figure 1). We evaluated the activity 65 
of these molecules in an in vivo preclinical model of pancreatic cancer. [4] We showed that while the 66 
multitarget strategy is not needed for the antitumor activity (the sole N,N-dimethylthiosemicarbazone 67 
chelating moiety is sufficient to confer cytotoxic action, as in compound ACthio-1, (Z)-N,N-68 
dimethyl-2-(2-oxoindolin-3-ylidene)hydrazinecarbothioamide, Figure 1), the presence of the sigma-69 
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2 targeting portion (as in compounds MLP44, (Z)-2-(1-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-70 
2(1H)-yl)butyl)-2-oxoindolin-3-ylidene)-N,N-dimethylhydrazinecarbothioamide and PS3, (Z)-2-[1-71 
[4-(4-cyclohexylpiperazin-1-yl)butyl]-2-oxoindolin-3-ylidene]-N,N-72 
dimethylhydrazinecarbothioamide, Figure 1) could result in diverse cell death pathways and in a more 73 
specific delivery to tumors, leading to reduced off-targets effects. [4] These promising results 74 
prompted us to produce a novel sigma-2 binding thiosemicarbazone, whose sigma-2 binding basic 75 
moiety was the 3H-spiro[isobenzofuran-1,4’-piperidine]. The overall structure mimicked the sigma-76 
2 reference compound siramesine, which was shown to be cytotoxic in a number of cells via pathways 77 
such as lysosomal leakage [10] and mitochondria destabilization [11] that lead to oxidative stress. 78 
[10–12] Insertion of such a moiety could result in an increased cytotoxic effect in pancreatic cancer 79 
cells, by combining the potent action of the sigma-2 ligand siramesine with the metal chelating moiety 80 
proper of the thiosemicarbazone within one scaffold. This novel compound named FA4, (Z)-2-(1-(4-81 
(3H-spiro[isobenzofuran-1,4’-piperidine]-1’-yl)butyl)-2-oxoindolin-3-ylidene)-N,N-82 
dimethylhydrazinecarbothioamide (Figure 1), was studied in a panel of pancreatic cancer cells and 83 
challenged with our most promising thiosemicarbazones, either targeting sigma-2 receptors (MLP44 84 
and PS3) or not (ACthio-1). While all the thiosemicarbazones studied are cytotoxic in the diverse 85 
pancreatic cancer cells, the type/presence of the basic moiety triggers different pathways in the 86 
diverse cells, a result that looks promising in the perspective of a personalized medicine approach. 87 
Additionally, the novel compound performed better than the other thiosemicarbazones in all the 88 
pancreatic tumor cell lines, with important cytotoxic action in the human aggressive PANC-1 cells, 89 
which display a reduced sensitivity to the first-line treatment gemcitabine against which they 90 
eventually develop resistance. [13] The in vitro results were also confirmed in PANC-1 xenografts 91 
shedding light on the potentials of FA4 in the treatment of pancreatic tumors. 92 
 93 
Results  94 
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Chemistry  95 
According to a previously set up procedure, FA4 was synthesized starting from the alkylation of the 96 
3H-spiro[isobenzofuran-1,4’-piperidine] [14] with 1-(4-chlorobutyl)indoline-2,3-dione 1 in the 97 
presence of K2CO3, [2] providing the amine 2. This intermediate amine was transformed into its 98 
corresponding hydrochloride salt, dissolved in hot EtOH and treated with 4,4-dimethyl-3-99 
thiosemicarbazide to afford final thiosemicarbazone FA4 as hydrochloride salt (Scheme S1, 100 
Supplementary Information). The synthetic experimental procedures are reported in the 101 
Supplementary Information. 102 
 103 
Affinity of FA4 at the sigma-2 receptors by radioligand binding assay 104 
The binding of FA4 at sigma-2 receptors measured through by classical radioligand binding assay 105 
was notable (Ki = 15.8 nM, Table 1) and in strict agreement with the binding affinity of the siramesine 106 
lead compound (Ki = 12.6 nM) [8] showing how the thiosemicarbazone moiety was not detrimental 107 
for the sigma-2 receptor binding.  108 
 109 
Density of sigma-2 receptors and binding affinity of FA4 in tumor and normal (immortalized) 110 
pancreatic cells 111 
The presence of sigma-2 receptors was evaluated in a panel of pancreatic cells. Flow cytometry 112 
analyses in the human (MiaPaCa2, PANC-1, AsPC1 and BxPC3) and murine (KP02, PANC02) 113 
adenocarcinoma pancreas cells together with HPDE cells were conducted for this aim. The assay was 114 
performed by incubating each cell line with increasing concentrations of the selective sigma-2 115 
fluorescent ligand NO1. [15,16] Saturation of the sigma-2 receptors in each cell line and definition 116 
of the non-specific binding through displacement with DTG led to define the specific binding. Results 117 
clearly indicate that sigma-2 receptors are from 1.8- to 3.2-fold more expressed in adenocarcinoma 118 
pancreatic cells than in HPDE cells (Figure S1 – A, Supplementary Information). The only exception 119 
is the KP02 cell line in which the density of sigma-2 receptors is comparable to the density in HPDE 120 
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cells. By means of the flow cytometry, we measured the binding affinity of FA4 at sigma-2 receptor 121 
subtypes in the pancreatic cells according to the previously set up procedures. [15] Binding curves 122 
were generated for the thiosemicarbazone, upon dose-dependent displacement of the fluorescent 123 
ligand NO1 [15] with FA4 leading to IC50 values that line up with the results from the radioligand 124 
binding assay (IC50 values ranging from 9.13 nM to 11.6 nM in MiaPaCa2, PANC-1, Aspc1 and 125 
KP02, Table 1), showing an equally high nanomolar affinity in these representative cell lines.  126 
 127 
Density of sigma-1 receptors and binding affinity of FA4 in tumor and normal (immortalized) 128 
pancreatic cells 129 
Because in our hands siramesine binds equally well the sigma-1 and sigma-2 receptor subtypes, [8] 130 
we investigated the presence of sigma-1 receptors together with the binding of FA4 for this subtype 131 
in the clinically relevant pancreatic cancer cells (PANC-1 and MiaPaCa2). The sigma-1 fluorescent 132 
ligand LM1 [17] was used to measure the sigma-1 receptor density in the above cells and HPDE cells 133 
upon masking of the sigma-2 subtype with the selective sigma-2 ligand F390 [18] (Figure S1 – B, 134 
Supplementary Information). The presence of the sigma-1 receptor was ascertained, with no 135 
difference in the amount between the tumor and immortalized cells, in contrast to the sigma-2 136 
receptor. Additionally, the binding curves generated upon dose-dependent displacement of LM1 in 137 
PANC-1 and Miapaca-2 led to define a moderate affinity of FA4 for sigma-1 receptors (IC50 values 138 
= 51.3 and 53.2 nM, respectively, Table 1), suggesting a more pronounced sigma-2 than sigma-1 139 
mediated action of FA4 in the biological assays. 140 
 141 
Cytotoxic activity of FA4 in tumor and normal (immortalized) pancreatic cells 142 
The cytotoxic activity of the novel thiosemicarbazone FA4 was evaluated in human (MiaPaCa2, and 143 
PANC-1, AsPC1 and BxPC3,) and murine (KP02, PANC02) pancreatic adenocarcinoma cells with 144 
diverse driver mutations (Table 2). FA4 demonstrated relevant low micromolar cytotoxic activity in 145 
all the cell lines studied (EC50 ranging from 0.88 M to 3.01 M, Table 2). In particular, in PANC-146 
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1, MiaPaCa2 and KP02 cells, FA4 activity was from 3- to 8-fold higher compared to the cytotoxicity 147 
conferred by the other sigma-2 targeting thiosemicarbazones MLP44 and PS3. Cytotoxicity of all 148 
thiosemicarbazones was also measured in HPDE cells where the compounds generally showed a less 149 
potent activity than in the adenocarcinoma cells, but again, only FA4 consistently displayed a 2- to 150 
7- fold lower cytotoxicity (EC50 = 6.11, Table 2).  151 
 152 
FA4 induces cell apoptosis by eliciting endoplasmic reticulum stress and mitochondrial damage 153 
First, we investigated whether the compounds induced apoptosis, an effect that has been already 154 
reported for sigma-2 receptors ligands in cancer cells. [3,19,20] We first measured the activity of 155 
caspase 3, i.e. the caspase that irreversibly determines apoptotic death, in human MiaPaCa2, PANC-156 
1, and AspC1 and in murine KP02 and PANC02 cells, treated with sigma-2 targeting 157 
thiosemicarbazones FA4, MLP44, PS3, and metal chelator ACthio-1 (Figure 2), in the same 158 
experimental conditions (50 µM for 2 h) in which sigma-2 receptors ligands induced cytotoxic effects 159 
against pancreatic cancer cells [3]. FA4 activated caspase 3 in all the cell lines investigated, while the 160 
other compounds activated caspase 3 in a variable and cell-dependent manner. For instance, the other 161 
thiosemicarbazones did not activate caspase 3 in MiaPaCa2 and AspC1, but they activated caspase 3 162 
in murine PANC02 and KP02 cells, in partial agreement with previous findings. [4] 163 
Moreover, FA4 was the most potent inducer of caspase 3 in all cell lines compared to the other 164 
compounds (with the only exception of ACthio-1 having similar activity in KP02).  165 
Notably, FA4 was a significant inducer of caspases in all the cell lines analyzed, except for MiaPaCa2 166 
cells, also when used at the concentration corresponding to its IC50 in each cell line (Supplementary 167 
Figure S2). 168 
To better investigate the biochemical mechanisms of FA4 and the other compounds in inducing 169 
apoptosis, we first focused on the effects exerted on endoplasmic reticulum (ER), an intracellular 170 
compartment where sigma-2 receptors have been reported. [21] 171 
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Sigma-2 receptors are known inducers of ER stress, a condition that perturbs the correct folding of 172 
proteins within the ER and causes the so-called unfolded protein response (UPR). UPR is sensed by 173 
the chaperone glucose-regulated protein 78 (GRP78) and by the sensors activating factor 6 (ATF6), 174 
inositol-requiring enzyme-1α (IRE-1α) and PKR-like ER kinase (PERK) that activate downstream 175 
effectors leading to cell survival if the ER stress is short and reversible, or cell apoptosis by activating 176 
the caspase 7/caspase 3 axis if the stress persists. [22] By altering calcium flux, sigma-2 receptors 177 
modulators are known to induce ER stress [23] and promote cell death by activating apoptotic and 178 
autophagic pathways.  [24] 179 
The mRNA expression of ER stress markers such as GRP78, ATF6, IRE1 and PERK were evaluated 180 
in all the pancreatic cancer cells studied (Figure 3A). The four ER stress markers increased upon 181 
treatment with FA4 in all the cells except for MiaPaCa2 cells. All the thiosemicarbazones increased 182 
the mRNA expression of these markers in PANC-1, whereas none of the markers was increased in 183 
the other cells by MLP44, PS3 and ACthio-1. The increase of ER stress induced by FA4 was 184 
validated by the immunoblotting of GRP78, ATF6, IRE1 and PERK (Figure 3B): the results 185 
confirmed that in all cell lines except MiaPaCa2, this thiosemicarbazone was able to increase the 186 
expression of ER stress sensors and executers. Notably, FA4 increased the expression of ER stress 187 
markers also when used at its IC50 concentration (Supplementary Figure S3). In agreement with the 188 
ER stress markers gene expression modulation, caspase 7, which is activated upon ER stress, was 189 
activated by FA4 in all cell lines except for MiaPaCa2 cells (Figure 2, Supplementary Figure S2). 190 
Similarly, all the thiosemicarbazones increased caspase 7 in PANC-1 cells, while the behavior in the 191 
other cell lines was highly variable. The activation of caspase 7 may be responsible for the activation 192 
of the downstream caspase 3, although the extent of caspase 7 and caspase 3 activation are not always 193 
comparable in the same cell lines treated with the same compound. These small discrepancies may 194 
be due to different pool of pro-apoptotic and anti-apoptotic factors that each cell line has and may be 195 
affected differently by the compounds. Alternatively, other mechanisms converging on the activation 196 
of caspase 3 could be hypothesized. 197 
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The alteration of calcium homeostasis in the so-called Mitochondria-associated ER membranes 198 
(MAM) also alters mitochondria metabolic functions, leading to calcium overload, increased 199 
production of reactive oxygen species (ROS), mitochondrial depolarization followed by the activation 200 
of cell death triggered by caspase 9/caspase 3 axis and autophagy. [25] Importantly, sigma receptors, 201 
have been found in the MAM cell compartments, where in particular the sigma-1 subtype regulates 202 
Ca2+ fluxes between the ER and mitochondria. [26] 203 
We thus focused on mitochondria-related events as possible triggers of additional pro-apoptotic 204 
mechanisms. Interestingly, FA4 increased mitochondrial ROS in all the cell lines except for 205 
MiaPaCa2, whereas the other thiosemicarbazones increased mitochondrial ROS only in PANC-1 and 206 
PANC02 (Figure 4). The levels of ROS in whole cells (Figure 4) reflected the levels of mitochondrial 207 
ROS, suggesting that ROS can diffuse from mitochondria to cytosol. Alternatively, we may speculate 208 
that thiosemicarbazones are able to increase ROS also in a mitochondria-independent way, e.g. by 209 
increasing cytosolic ROS-producing enzymes such as NADPH oxidase or reducing the activity of 210 
anti-oxidant enzymes, such as superoxide dismutase 1, catalase, peroxidases, thioredoxins.  211 
Preliminary data on the activity of NADPH oxidase, superoxide dismutase 1 and catalase 212 
(Supplementary Figure S4), however, seems to exclude this second hypothesis.  213 
The increase in mitochondrial ROS was harmful in treated cancer cells. Indeed, the staining with JC1, 214 
a dye sensitive to the mitochondrial depolarization, indicated that all FA4-treated cells had 215 
depolarized (i.e. damaged) mitochondria, except for MiaPaCa2 (Figure 4). The other 216 
thiosemicarbazones increased mitochondria depolarization only in PANC-1 and PANC02 cells, not 217 
in the other cell lines (Figure 4). This parallelism between mitochondrial ROS and depolarization 218 
suggests that the latter event is consequent to the increased mitochondrial ROS. Mitochondria damage 219 
triggers the activation of caspase 9, and this event was observed in all the cells where FA4 increased 220 
mitochondrial ROS and depolarization (Figure 2,4). By contrast, the other compounds had a variable 221 
activation of the caspase, dependent on the cell line and not strictly correlated with mitochondrial 222 
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ROS and depolarization. Again, MiaPaCa2 cells were completely refractory to the activation of 223 
caspase 9 (Figure 2). 224 
As proof of concept that mitochondrial ROS triggered the cell death induced by FA4, we treated cells 225 
with the mitochondrial ROS scavenger mitoquinol (mitoQ), at a concentration that abrogated the 226 
increase of mitochondrial ROS elicited by FA4 (Figure 5A): in these experimental condition we did 227 
not find any activation of caspase 9 and caspase 3 in FA4-treated cells (Figure 5B-C).  228 
To explain the absence of activation of ER stress- and mitochondrial stress-dependent pro-apoptotic 229 
pathways in MiaPaCa2 cells, in contrast with the other cell lines, we investigated whether cells differ 230 
for autophagy that contributes to the apoptosis induced by sigma-2 receptors following ER [24] or 231 
mitochondrial [25] stress. Interestingly, all PDAC responsive cell lines have higher levels of 232 
autophagosome proteins (ATG5, ATG7, ATG12, beclin 1), sequestration markers (p62) and LC3-233 
II/LC3-I ratio than MiaPaCa2 cells. Moreover, FA4 reduced the levels of all the above-mentioned 234 
protein and the LC-I/LC-II conversion in responsive cells but not in MiaPaCa2 cells (Figure 6).  235 
 236 
In vivo antitumor activity of FA4  237 
The potent in vitro antitumor activity shown by FA4 in the aggressive human PANC-1 cells prompted 238 
us to investigate whether the anticancer effect is translated in vivo as well. In a first experiment, 239 
PANC-1 and MiaPaCa2 xenografts were treated for 15 days with two dosages (low and high) of FA4, 240 
following the protocol adopted for other thiosemicarbazones. [4] Gemcitabine was used as 241 
comparison, because it is the standard treatment in pancreatic cancers. At the end of the treatments, 242 
tumors were significantly smaller for mice treated with FA4 750 low and FA4 1500 high compared to 243 
vehicle in PANC-1 xenografts. An important reduction in tumor volume for both FA4 regimens was 244 
also recorded in PANC-1 tumors in comparison with mice treated twice weekly by gemcitabine that 245 
was ineffective against this tumor cell line (Figure S5A, Supplementary Information). By contrast, 246 
MiaPaCa2 tumors were more sensitive to gemcitabine, but- in line with the data observed in vitro - 247 
FA4 was ineffective at both dosages (Figure S5B, Supplementary Information).  248 
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In a second experimental set, we prolonged the treatment of PANC-1 tumor-bearing animals for 30 249 
days, to evaluate the effects in terms of tumor growth rate and systemic toxicity. In these conditions, 250 
while gemcitabine was not able to reduce significantly tumor growth, FA4 at the low dosage showed 251 
a cytostatic effect and FA4 at higher dosages a regression of tumor growth (Figure 7A-B). Moreover, 252 
in line with the apoptosis and the increased ROS observed in PANC-1 cells, the intratumor apoptosis, 253 
measured as positivity of cleaved caspase 3, and the lipid peroxidation, considered an index of 254 
intratumor oxidative stress, were low or undetectable in untreated and gemcitabine-treated animals, 255 
as well as in animals treated with low dosages of FA4, but they became more pronounced in tumors 256 
from animals treated with high dosages of FA4 (Figure 7C-D). No treatment-related deaths, weight 257 
loss or abnormalities in mouse behavior were observed during treatment. Blood cells count and 258 
hematochemical parameters (AST, ALT, LDH, CPK, creatinine) were measured and no significant 259 
differences were noted between FA4 treated mice (at both the concentrations used) and when 260 




Discussions  263 
Multifunctional thiosemicarbazones that bind sigma receptors and chelate metals had provided 264 
promising results in pancreatic cancer models both in vitro and in vivo. Herein, a panel of human  and 265 
murine adenocarcinoma pancreatic cells genotypically and phenotypically different [27] were 266 
selected since previous experiments have well shown how diverse pancreatic cancer cells differently 267 
respond to the chemotherapeutic agents. [4] In all the cell lines, the presence of the sigma-2 receptors 268 
was evaluated by flow cytometry analyses: the expression of sigma-2 receptor in the adenocarcinoma 269 
cells was from 2 to 3 –fold higher compared to the non-tumor epithelial cells. On the other hand, the 270 
sigma-1 receptor subtype was equally expressed in the human pancreatic cancer cells and in the non-271 
tumor immortalized counterparts. The binding affinity of the novel thiosemicarbazone FA4 for 272 
sigma-2 receptors was evaluated by the classical radioligand binding assay revealing a low nanomolar 273 
Ki value consistent with the Ki of the lead compound siramesine. Binding affinities of FA4 were also 274 
measured by flow cytometry analyses in the pancreatic cancer cells in which FA4 cytotoxic effect 275 
mechanisms were herein investigated, revealing similar low nanomolar IC50 values in all the cells 276 
(IC50 values around 10 nM). Because FA4 structure mimics siramesine’s, we also measured binding 277 
affinity of FA4 for sigma-1 receptor, as in our hands siramesine binds the two sigma subtypes equally 278 
well. [8] Despite the fact that a 5-fold lower affinity of FA4 for sigma-1 receptor compared to the 279 
sigma-2 receptor was found (IC50 values around 50 nM), the sigma-1 receptor implication in the 280 
overall activity, although more marginal, cannot be ruled out. 281 
Except for the murine PANC02 cells, FA4 displayed a 3- to 8-fold more potent cytotoxic activity 282 
compared to the already known thiosemicarbazones (MLP44, PS3 and ACthio-1) in all the 283 
adenocarcinoma cells investigated. Worthy of note is the activity of FA4 in PANC-1, that is an 284 
aggressive cell line of clinical importance that eventually develops resistance to gemcitabine. [13] 285 
Indeed, while other sigma-2 ‘pure’ ligands (devoid of metal chelation activity) [3] and the ‘pure’ 286 
metal chelator thiosemicarbazone ACthio-1 (devoid of sigma-2 affinity) did not display cytotoxicity 287 
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in PANC-1 cells, the synergistic effect proper of the multifunctional agents seem to be a winning 288 
strategy in this cell line. Indeed, thiosemicarbazones carrying the sigma-receptor targeting basic 289 
moiety (PS3, MLP44, FA4) exert cytotoxicity in PANC-1 cells. In our hands, the best results were 290 
so far reached by the sigma-2 targeting thiosemicarbazones MLP44 and PS3, but FA4 performed 291 
better, with a more potent activity in PANC-1 cells and a lower cytotoxicity in non-tumor cells. 292 
Although HPDE cells are immortalized and do not exactly recapitulate the non-transformed epithelial 293 
pancreatic cells, this data gives an indication of a selective activity of FA4 towards cancer cells rather 294 
than towards non-transformed cells. An important cytotoxic activity compared to the other 295 
thiosemicarbazones was also shown by FA4 in the MiaPaCa2 cell line, another widely used 296 
pancreatic cancer model, although less aggressive and more sensitive to gemcitabine than PANC-1. 297 
[13] 298 
The encouraging results from the cytotoxicity assays, that demonstrate a ‘superior’ activity of FA4 299 
in pancreatic cancer cells compared to the previously generated thiosemicarbazones, prompted us to 300 
analyze the possible apoptotic pathways induced by the four thiosemicarbazones (FA4, MLP44, PS3 301 
and ACthio-1) in our panel of diverse pancreatic adenocarcinoma cells. ER- dependent (ER stress 302 
sensors, caspase 7/caspase 3 axis) and mitochondria-dependent pathways (mitochondrial ROS and 303 
depolarization, caspase 9/caspase 3 axis) revealed variable activation of the apoptotic pathways 304 
dependent on ER and mitochondria, that depend on the cell line. The variegate results demonstrate 305 
that different pancreatic cells treated with the same compound undergo to cell death pathways to 306 
different extent and with different prevailing mechanisms. It is also clear as the modification of the 307 
basic moiety in these thiosemicarbazones leads to the activation of diverse pathways, dependent on 308 
ER or mitochondria. Noteworthy, FA4 induces apoptosis and ER stress in all cell lines except for 309 
MiaPaCa2 cells, when used at its IC50 concentration that is in the low micromolar range. Although 310 
obtained in vitro, this result indicates a promising cytotoxic potential of FA4 at concentrations that 311 
could be reached in preclinical models or even in clinical settings. The differential sensitivity of 312 
pancreatic cancer cell lines to FA4 and other thiosemicarbazones may be due to several and 313 
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interconnected factors, including the reactivity of ER stress mechanisms, the vulnerability of 314 
mitochondria to the ROS-induced damage, the activity of autophagy. 315 
Notably, while the other thiosemicarbazones have a variable effect on the activation of ER- or 316 
mitochondria-dependent pro-apoptotic axis, FA4 activates both pro-apoptotic pathways in each cell 317 
line except for MiaPaCa2. The opposite behavior between MiaPaCa2 and the other cell lines indicates 318 
that the differences in the genotype and biochemical pathways of each cell line may widely affect the 319 
ability of slightly different thiosemicarbazones to drive or prevent pro-apoptotic pathways. At least 320 
two differences emerged between MiaPaCa2 and the other cell lines. First, in MiaPaCa2 cells FA4 321 
did not induce any increase in mitochondrial ROS that were the primum movens of the apoptosis 322 
induced by this thiosemicarbazone, according to the protective role of mitoQ. Second, we noticed 323 
different expression levels of authophagosome proteins and sequestration markers. This observation 324 
may have a relevant biological meaning because autophagy has been linked to the apoptotic 325 
mechanism activated by sigma-2 receptor. Importantly, pancreatic tumor cells less prone to undergo 326 
autophagic pathways are less responsive to therapy. [28] The results that autophagic proteins are less 327 
expressed in MiaPaCa2 cells compared to the other cell lines, suggest that MiaPaCa2 cells may be 328 
less reactive to cell death mechanisms induced by ER stress and mitochondrial damage elicited by 329 
FA4, due to a low autophagy. On the other hand, it is known that autophagy may play either a pro-330 
tumor or an anti-tumor effect in pancreatic cancer [29]. Intriguingly, FA4 reduced the expression of 331 
specific autophagosome proteins and sequestration markers in all responsive cell lines, but not in 332 
MiaPaCa2 cells. We hypothesize that FA4 prevents the protective/anti-tumor effect of autophagy in 333 
pancreatic cancer cells. By contrast, FA4-unresponsive MiaPaCa2 cells, which have a low and not 334 
tunable autophagy, are protected from FA4. These results suggest that the increase of  mitochondrial 335 
ROS and/or the decrease in specific autophagic markers induced by FA4 are important in amplifying 336 
the cytotoxicity of FA4 following ER stress and mitochondrial damage.  337 
The promising cytotoxicity recorded in vitro, prompted to evaluate how FA4 performed in xenografts 338 
in vivo. Our results showed that also the lower concentration of FA4 was able to significantly reduce 339 
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tumor volume compared to control and gemcitabine. The effects observed in xenografts recapitulated 340 
the viability data observed in vitro. Indeed, FA4 effectively reduced tumor growth of PANC-1 341 
tumors, but not of MiaPaCa2 tumors. This result is of particular interest because PANC-1 xenografts 342 
were more resistant to gemcitabine than MiaPaCa2 xenografts. We recognize that we only compared 343 
one FA4-sensitive/gemcitabine resistant pancreatic tumor and one FA4-resistant/gemcitabine 344 
sensitive pancreatic tumor, but according to our data, we might speculate that FA4 could be proposed 345 
as an alternative to gemcitabine in tumors unresponsive to the first line treatment. At short term, i.e. 346 
after 15 days of treatment, we could no detect a tumor regression in PANC-1 xenografts treated with 347 
FA4, but only a significant delay in tumor growth, followed by a cytostatic effect when animals were 348 
treated with the higher dosage of FA4. Since apoptosis dependent on ER stress and mitochondria 349 
depolarization is not the only mechanisms that can induce tumor regression, we may hypothesize that 350 
other driving factors, not affected by FA4, continue to stimulate tumor growth. Alternatively, we 351 
could not exclude that our treatment was too short to appreciate a pronounced apoptotic effect of 352 
FA4, able to determine tumor regression. To clarify this point and to deepen the safety profile of 353 
FA4, we doubled the time of treatment of PANC1 xenografts up to 30 days. In these conditions, the 354 
efficacy of FA4 was amplified: indeed, the low dosage produced a cytostatic effect, while the high 355 
dose induced a tumor regression, likely due to the strong intratumor apoptosis. These data suggest 356 
that FA4 is a well-tunable agent, able to exert either cytostatic or cytoreductive effects depending of 357 
the time and dosage chosen. Importantly, no signs of toxicity were recorded during and after 358 
treatment. Notably, in xenograft experiments, we used two concentrations (750 nM and 1.5 µM) that 359 
were below the IC50 of FA4 (3.01 µM) in PANC1 cells. When used at the same concentration of its 360 
IC50, FA4 activated the key mechanism related to its cytotoxic effect, i.e. the ER stress-dependent 361 
and the mitochondrial damage-dependent apoptosis in PANC1 cells. FA4-treated tumors 362 
recapitulated these events, as suggested by the increased intratumor active caspase 3 and by the 363 
increased lipid peroxidation, indicative of oxidative damage. These data suggest that the cytotoxic 364 
mechanisms observed in vitro also occur intratumorally. 365 
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In conclusion, through the use of metal chelator thiosemicarbazones targeting sigma receptors, (FA4, 366 
MLP44, and PS3) and ACthio-1 (metal chelator), we have shown how small differences (i.e. diverse 367 
basic moiety) in the structure of thiosemicarbazone congeners lead to the activation of different 368 
pathways in the same cell types. Importantly, diverse cells undergo different pathways when treated 369 
with the same compound. These differences should be taken into account in the perspective of a 370 
personalized medicine based approach with therapies that can more efficiently target the peculiar 371 
characteristics of each tumor type. Additionally, the presence of the sigma-2 receptor targeting moiety 372 
may result in a more specific tumor delivery, given the higher density of these receptors in pancreatic 373 
tumors. Last but not the least, FA4 provided promising antitumor activity in the aggressive PANC-1 374 
preclinical tumor model, that is resistant to gemcitabine and is a prototypical example of pancreatic 375 
cancer that urgently needs novel treatment options. Our work highlights the potential of FA4 as 376 
possible monotherapy against PDAC unresponsive to gemcitabine, as an alternative to the 377 
pharmaceutical strategies currently in use. Altogether, the results obtained encourage further studies 378 
to define FA4 profile in patient-derived pancreatic adenocarcinomas, particularly for those tumors 379 
that, like PANC-1, are unresponsive to the conventional chemotherapy. 380 
 381 
Materials and Methods 382 
Biological Reagents 383 
[3H]-DTG (29 Ci/mmol) was purchased from PerkinElmer Life Sciences (Zavantem, Belgium). DTG 384 
was purchased from Tocris Cookson Ltd., U.K. (+)-Pentazocine was obtained from Sigma-Aldrich-385 
RBI s.r.l. (Milan, Italy). Wistar Hannover rats (250-300 g) was from Harlan, Italy. Cell culture 386 
reagents were purchased from EuroClone (Milan, Italy). MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-387 
diphenyltetrazoliumbromide), was obtained from Sigma-Aldrich (Milan, Italy). [10-(2,5-dihydroxy-388 
3,4-dimethoxy-6,ethylphenyl)decyl]triphenyl-phosphonium, monomethanesulfonate (mitoquinol or 389 
mitoQ) was from Cayman Chemical (Ann Arbor, MI). 390 
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Cell Culture 391 
Human pancreas adenocarcinoma cancer cell lines BxPC3 (CRL-1687™), AspC1 (CRL-1682™), 392 
MiaPaCa2 (CRL-1420™), and PANC-1 (CRL-1469™) were obtained from American Type Culture 393 
Collection (ATCC®, Bethesda, MD). The murine PANC02 pancreas adenocarcinoma was a gift from 394 
Bryan Clary (Duke University). The KP02 mouse line was derived from pancreatic cancer tumor 395 
tissue obtained from p48-CRE/LSL-KrasG12D/p53flox/+ mice (backcrossed C57BL/6, n = 6). Non-396 
tumor human pancreatic ductal epithelial (HPDE) cells were provided by Kerafast (cat. N° ECA001-397 
FP, Boston, MA). AspC1, BxPC3 and PANC02 cells were cultured in RPMI-1640 medium with 10% 398 
fetal bovine serum (FBS). MiaPaCa2 cells were cultured in Dulbecco’s Modified Eagle’s Medium 399 
(DMEM) with 10% FBS and 2.5% horse serum. PANC-1 cells were cultured in DMEM with 10% 400 
FBS. KP02 cells were cultured in 1:1 mixture of DMEM and Ham’s F-12 Nutrient Mixture with 10% 401 
FBS. HPDE were cultured in Keratinocyte/serum-free medium with EGF and bovine pituitary extract 402 
(Invitrogen). Penicillin (100 mg/mL) and streptomycin (100 mg/mL) were added to all media; cells 403 
were maintained in a humidified incubator at 37 ºC with 5% CO2. 404 
 405 
Flow Cytometry studies 406 
Flow cytometry studies to detect sigma receptors density and ligand binding affinity were carried out 407 
according to Abate et al 2016 [17] and Niso et al 2015 [15], for sigma-1 and sigma-2 receptor, 408 
respectively. In order to detect the sigma-2 receptor content in pancreatic cells together with the 409 
affinity of FA4 for sigma-2 receptors in the same cells, MiaPaCa2, PANC-1 BxPC3, PANC02, KP02, 410 
AspC1 and HPDE cells were incubated with increasing concentrations (1, 10, and 100 nmol/L and 1 411 
and 10 µM) of FA4, followed by 100 nmol/L of sigma-2 fluorescent compound (NO1, 2-{6-[2-(3-412 
(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-3,4-dihydroisoquinolin-1(2H)-one-5-413 
yloxy]hexyl}-5-(dimethylamino)isoindoline-1,3-dione) [15] for 75 min at 37 °C. To mask sigma-1 414 
receptors, (+)-pentazocine (10 µM) was co-incubated. The same experiment was repeated with the 415 
sigma-2 reference compound DTG in place of FA4, as a validation procedure.  416 
18 
 
At the end of the incubation periods, cells were washed twice with PBS, detached with 200 mL of 417 
Cell Dissociation Solution (Sigma Chemical Co.) for 10 min at 37 °C, centrifuged at 13,000 g for 5 418 
min and resuspended in 500 µL of PBS. The fluorescence was recorded using a Bio-Guava® 419 
easyCyte™ 5 Flow Cytometry System (Millipore, Billerica, MA), with a 530 nm band pass filter. For 420 
each analysis, 50,000 events were collected and analyzed with the InCyte software (Millipore).  421 
Sigma-1 receptor density and FA4 binding to sigma-1 receptors was measured in PANC-1, MiaPaCa2 422 
and HPDE cells that were incubated with increasing concentrations (1, 10, and 100 nmol/L and 1 and 423 
10 µM) of (+)-pentazocine or FA4, followed by 100 nmol/L of sigma-1 fluorescent compound (LM1, 424 
5-(dimethylamino)-2-(6-((5-(4-(4-methylpiperidin-1-yl)butyl)-5,6,7,8-tetrahydronaphthalen-2-425 
yl)oxy)hexyl)isoindoline-1,3-dione) [17] for 75 min at 37 °C. To mask sigma-2 receptors the sigma-426 
2 receptor selective ligand F390, 2-(3-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-5-427 
methoxy-3,4-dihydroisoquinolin-1(2H)-one [18] (10 µM) was co-incubated. At the end of the 428 
incubation periods, cells were washed twice with PBS, detached with 200 mL of Cell Dissociation 429 
Solution (Sigma Chemical Co.) for 10 min at 37 °C, centrifuged at 13,000 g for 5 min and resuspended 430 
in 500 µL of PBS. The fluorescence was recorded using a Bio-Guava® easyCyte™ 5 Flow Cytometry 431 
System (Millipore, Billerica, MA), with a 530 nm band pass filter. For each analysis, 50,000 events 432 
were collected and analyzed with the InCyte software (Millipore).  433 
 434 
Sigma-2 binding by radioligand studies 435 
Sigma-2 receptor binding was carried out according to Berardi et al 2009. [30] [3H]-DTG was used 436 
as sigma-2 receptor specific radioligand in the presence of 1 μM (+)-pentazocine to mask sigma-1 437 
receptors, in rat liver membranes. DTG (85-96%) was used for the specific binding calculation. 438 
Concentrations required to inhibit 50% of radioligand specific binding (IC50) were determined by 439 
using six to nine different concentrations of the drug studied in two or three experiments with samples 440 
in duplicate. Scatchard parameters (Kd and Bmax) and apparent inhibition constants (Ki) values were 441 




Cell Viability 444 
Determination of cell growth was performed using the MTT assay at 48 h. [3,31] On day 1, 25,000 445 
cells/well were seeded into 96-well plates in a volume of 100 μL. On day 2, the drugs at  446 
concentrations ranging from 1 μM to 100 μM were added. In all the experiments, the various drug-447 
solvents (EtOH, DMSO) were added in each control to evaluate a possible solvent cytotoxicity. After 448 
the established incubation time with drugs (48 h), MTT (0.5 mg/mL) was added to each well, and 449 
after 3-4 h incubation at 37 °C, the supernatant was removed. The formazan crystals were solubilized 450 
using 100 μl of DMSO/EtOH (1:1) and the absorbance values at 570 and 630 nm were determined 451 
on the microplate reader Victor 3 from PerkinElmer Life Sciences. 452 
 453 
Caspase 3, 7 and 9 activity 454 
Caspase 3, caspase 7 and caspase 9 activation were measured by using the Caspase 3/7 Fluorescence 455 
Assay kit (Cayman Chemical, Ann Arbor, MI) and the Caspase 9 fluorimetric assay kit (Enzo Life 456 
Science, Roma, Italy). The results are expressed as nmol of the hydrolyzed substrate of each 457 
caspase/mg cellular proteins, according to a previously set titration curve. 458 
 459 
qRT-PCR 460 
Total RNA was extracted by phenol/chloroform method. 1 μg RNA was reverse-transcribed using 461 
the iScript Reverse Transcription Supermix kit (Bio-Rad Laboratories), according to the 462 
manufacturer’s instruction. 25 ng cDNA were amplified with 10 μL IQTM SYBR Green Supermix 463 
(Bio-Rad Laboratories). Primers were designed with the qPrimer Depot software 464 
(http://primerdepot.nci.nih.gov/). qRT-PCR was carried out with a iQTM5 cycler (Bio-Rad 465 
Laboratories). Cycling conditions were: 30 s at 95°C, followed by 40 cycles of denaturation (15 s at 466 
95°C), annealing/extension (30 s at 60°C). The same cDNA preparation was used to quantify the 467 
genes of interest and the housekeeping gene S14, used to normalize gene expression. The relative 468 
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quantitation of each sample was performed using the Gene Expression Quantitation software (Bio-469 
Rad Laboratories). Results were expressed in arbitrary units. For each gene, the expression in 470 
untreated cells was considered “1”. 471 
 472 
Mitochondrial and total ROS measurement 473 
Intramitochondrial ROS was measured using the fluorescent probe MitoSOX (Invitrogen), as per 474 
manufacturer’s instruction. To measure total ROS, cells were incubated with the ROS–sensitive probe 475 
5-(and-6)-chlorometyl-20,70-dichlorodihydro-fluorescein diacetate-acetoxymethyl ester (5 mmol/L; 476 
DCFDA-AM), as described by Riganti et al 2015. [32] The results are expressed as nmol/mg 477 
mitochondrial or cellular proteins, respectively. 478 
 479 
Mitochondria depolarization 480 
Staining with JC-1 fluorescent probe (Biotium Inc., Freemont, CA) was performed as detailed in 481 
Riganti et al 2015. [32] The fluorescence units were used to calculate the percentage of green-482 
fluorescent (i.e., depolarized) mitochondria versus red-fluorescent (i.e., polarized) mitochondria. 483 
 484 
Immunoblotting 485 
Cells were rinsed with ice-cold lysis buffer (50 mM, Tris, 10 mM EDTA, 1% v/v Triton-X100), 486 
supplemented with the protease inhibitor cocktail set III (80 μM aprotinin, 5 mM bestatin, 1.5 mM 487 
leupeptin, 1 mM pepstatin; Calbiochem, San Diego, CA), 2 mM phenylmethylsulfonyl fluoride and 488 
1 mM Na3VO4, then sonicated and centrifuged at 13,000  g for 10 min at 4 oC. 20 μg protein extracts 489 
were subjected to SDS-PAGE and probed with the antibodies for: ATG5, ATG7, ATG12, beclin, 490 
p62, LC3, GRP78, ATF6, IRE-1α, PERK (all from Abcam, Cambridge, UK), followed by a 491 
peroxidase-conjugated secondary antibody (Bio-Rad Laboratories). The membranes were washed 492 
with Tris-buffered saline-Tween 0.1% v/v solution, and the proteins were detected by enhanced 493 
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chemiluminescence (Bio-Rad Laboratories). To check the equal control loading in lysates, samples 494 
were probed with an anti-β-tubulin (Santa Cruz Biotechnology Inc., Santa Cruz, CA) antibody.  495 
Activities of pro-oxidant and anti-oxidant enzymes. The activity of NADPH oxidase was measured 496 
in cell lysates, by a chemiluminescence-based assay reported by Tassone et al, 2017 [33]. Results 497 
were expressed as RLU/mg cellular proteins. Superoxide dismutase and catalase actibities were 498 
measured with the colorimetric Superoxide Dismutase Activity Assay kit (Abcam) and with the 499 
Catalase Activity Assay kit (Abcam), as per manufacturer’s instructions. Results were expressed as 500 
optical density (OD)/mg cellular proteins.  501 
In vivo experiments 502 
2 x 105 PANC-1 or Mia-PaCa2 cells were inoculated subcutaneously in the right flank of 6-week old 503 
C57BL/6 female nude mice (Charles River Laboratories Italia, Calco), housed (5 per cage) under 12 504 
h light/dark cycle, with food and drinking provided ad libitum. Tumor growth was measured daily by 505 
caliper, according to the equation (LxW2)/2, where L=tumor length and W=tumor width. When 506 
tumors reached the volume of 100 mm3, mice (n= 8/group) were randomized in the following groups 507 
and treated daily for 15 days or 30 days intraperitoneally as reported: 1) Vehicle group (100 µL saline 508 
solution); 2) FA4low group (750 nmol FA4 in 100µL saline solution); 3) FA4high group (1500 nmol 509 
FA4 in 100µL saline solution); 4) Gemcitabine group (20 mg/kg gemcitabine, twice a week). Tumor 510 
volumes and animals weight were monitored daily. Animals were euthanized at day 18 or 36 after 511 
randomization with zolazepam (0.2 ml/kg) and xylazine (16 mg/kg). Tumors were excised and 512 
paraffin-embedded. Sections were immuno-stained for cleaved caspase 3 (Cell Signalling technology, 513 
Danvers, MA) or with anti-malondialdehyde (Abcam) antibody, followed by a peroxidase-conjugated 514 
secondary antibody (Dako, Glostrup, Denmark). The sections were examined with a Leica DC100 515 
microscope (Leica, Wetzlar, Germany). The quantitation of the immunohistochemical analyses was 516 
performed with the ImageJ software (https://imagej.nih.gov/). The staining intensity was expressed 517 
as arbitrary units and was considered 1 in vehicle group. Red blood cells (RBC) count, hemoglobin 518 
(Hb), white blood cells (WBC) count, platelets (PLT) count, lactate dehydrogenase (LDH), aspartate 519 
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aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP), creatinine, 520 
creatine phosphokinase (CPK) were measured on blood samples collected immediately after 521 
euthanasia, using commercially available kits from Beckman Coulter Inc (Beckman Coulter, Miami, 522 
FL). In all studies, researchers analyzing the results were unaware of the treatments received by 523 
animals. The study complies with ARRIVE guidelines.  524 
 525 
Statistical analysis 526 
Unless specified, data plotting and statistical analysis were conducted using GraphPad Prism 5.0. 527 
Data were analyzed by applying the one-way repeated measures analysis of variance, and 528 
Bonferroni’s multiple comparison test followed as a post hoc test. Results are reported as mean  529 
SEM (standard error of the mean) of at least two to three independent experiments, performed in 530 
triplicate. Statistical significance was accepted at P < 0.05. 531 
 532 
Supplementary Information: Chemistry: experimental and Scheme S1; Hematochemical 533 
parameters of treated animals in Table S1; Density of sigma receptors in pancreatic cells by flow 534 
cytometry studies in Figure S1; Activation of caspase 3, 7, 9 in tumor pancreatic cells by FA4 535 
administered at its IC50 values in Figure S2; Immunoblot of GRP78, ATF6, IRE1 and PERK in tumor 536 
pancreatic cells treated with FA4 at its IC50 values in Figure S3; NADPH oxidase, superoxide 537 
dismutase 1 and catalase, activities in tumor pancreatic cells treated with FA4 in Figure S4; Growth 538 
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Table 1. Binding affinity values of FA4 and reference compounds at sigma receptors. 630 




Ki ± SEMa (n) 
Flow Cytometry,  
IC50 ± SEMa (M) 
 Sigma-2 Sigma-2 Sigma-1 
 Rat Liver MiaPaCa2 PANC-1 AspC1 KP02 MiaPaCa2 PANC-1 
FA4 15.8 ±3.6 9.13±1.1 11.4±2.3 10.6±2.2 11.6±1.5 53.2±5.6 51.3±4.3 
DTG 22.5±3.6 5.98±0.9 6.59±1.6 14.3±3.0 7.16±1.2   
(+)-pentazocine      12.8±2.1 29.3±3.9 




Table 2. Activity values of thiosemicarbazones compounds in pancreatic cell lines. 635 
Cmpd  Activity in pancreatic cell lines, EC50 ± SEMa (M) 
 Tumor cells Normal cells 
 MiaPaCa2 PANC-1 AspC1 BxPC3 KP02 PANC02  HPDE 
FA4 1.98±0.4 3.01±0.8 1.39±0.3 1.36±0.2 0.88±0.1 1.94±0.5  6.11±1.1 
MLP44b 14.6 14.6 2.01 2.34 6.92 1.33  9.50 
PS3b 10.08 8.73 3.86 6.15 7.32 1.17  5.35 
Acthio1b 18.3 >100 2.17 2.52 2.83 1.21  10.5 
 a Values represent the mean of n ≥ 3 separate experiments in duplicate ± SEM; b From ref [4] 636 
  637 
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Figure 1. Known (AcThio-1, PS3 and MLP44) and novel (FA4) thiosemicarbazones. 638 
  639 
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Figure 2. Activation of caspase 3, 7, 9 by thiosemicarbazones in pancreatic cell lines. Fluorimetric 640 
measure of caspase 3, 7, 9 in cells treated 2 h with 50 µM of each compounds. Results are means ± 641 
SEM (n = 3), P < 0.05.  642 
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Figure 3. ER markers in thiosemicarbazone-treated pancreatic cancer cells. A. mRNA expression 646 
of ER stress markers, measured by RT-PCR, in cells treated 2 h with 50 µM of each compounds. 647 
Results are means ± SEM (n = 3), P < 0.05. B. Immunoblot of GRP78, ATF6, IRE1 and PERK in 648 
the indicated cell lines incubated with FA4 at 50 µM for 2 h. The image is representative of three 649 
independent experiments. Tubulin was used as control of equal protein loading. 650 
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Figure 4. ROS and mithocondrial damage markers in thiosemicarbazones-treated pancreatic cell 663 
lines. Fluorimetric staining of mitochondrial ROS (MitoSOX staining, A), whole cell ROS (DCFDA-664 
AM probe, B) and mitochondria depolarization (JC1 staining, C) in cells treated 2 h with 50 µM of 665 
each compounds. Results are means ± SEM (n = 3), P < 0.05. 666 
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Figure 5. Mitochondrial ROS (A), activation of caspase 9 (B) and caspase 3 (C) in cells treated 2 h 669 
with 50 µM of FA4 alone or plus 0.4 µM mitoquinol, chosen as scavenger of mitochondrial ROS. 670 
Results are means ± SEM (n = 3), P < 0.05. 671 
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Figure 6. Markers of authophagy and protein sequestration in pancreatic cell lines. Immunoblot of 673 
the indicated proteins in cells treated 2 h with 50 µM of FA4. The image is representative of three 674 
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Figure 7. FA4 in C57BL/6 mice bearing PANC-1 tumors, treated for 30 days. 1) Vehicle group 680 
(black line, 100 µL saline solution); 2) FA4low group (red line, 750 nmoles FA4 in 100 µL saline 681 
solution); 3) FA4high group (yellow line, 1500 nmoles FA4 in 100 µL saline solution); 4) Gemcitabine 682 
group (green line, 20 mg/kg gemcitabine, twice a week). Animals were euthanized at day 36. A. 683 
Tumor growth. Results are means ± SEM (n = 8). ***P<0.001: FA4-groups vs vehicle (days 21-36); 684 
##P<0.001: FA4-groups vs gemcitabine (days 21-36); °°°P<0.001: FA4high-group vs FA4low-group 685 
(days 21-36). B. Representative photos of excised tumors. C. Immunohistochemical analysis of 686 
intratumor cleaved caspase 3 and malondialdehyde, as index of lipid peroxidation. The images are 687 
representative of each group of treatment. Ocular: 10X; objective: 20X. Bars: 50 µm. D. The 688 
quantitation of the immunohistochemical staining were performed with the Image J software. Results 689 
are means ± SEM (n = 8). ***P<0.001: FA4-groups vs vehicle; ##P<0.01, ###P<0.001: FA4-groups vs 690 








Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor 
activity in adenocarcinoma pancreatic models 
 
Mauro Nisoa#, Joanna Kopeckab#, Francesca Serena Abatematteoa, , Francesco Berardi a, Chiara 
Rigantib*, Carmen Abatea* 
 
aUniversità degli Studi di Bari ALDO MORO, Dipartimento di Farmacia-Scienze del Farmaco, Via 
Orabona 4, 70125 Bari. 
bDepartment of Oncology, University of Turin, via Santena 5/bis, 10126, Torino, Italy 
 
#Equally Contributing Authors 
 
*Corresponding Authors 
Chiara Riganti, via Santena 5/bis, 10126, Torino, Italy, +390116705857, chiara.riganti@unito.it 













Table of Contents (total of 6 pages) 
Chemistry, page S2, S3; 
Scheme S1, page S4; 
Table S1, Hematochemical parameters of treated animals, page S5; 
Figure S1, Density of sigma receptors in pancreatic cells by flow cytometry studies, page S6. 
Figure S2, Activation of caspase 3, 7, 9 in tumor pancreatic cell lines by FA4 administered at its 
IC50 concentration, page S7; 
Figure S3, Immunoblot of GRP78, ATF6, IRE1 and PERK in tumor pancreatic cell lines treated 
with FA4 administered at its IC50 concentration, page S8; 
Figure S4, Pro-oxidant (NADPH oxidase) and anti-oxidant (superoxide dismutase 1, catalase) 
enzymes’ ativities in tumor pancreatic cells treated with FA4, page S9.  




Column chromatography was performed with 60 Å pore size silica gel as the stationary phase (1:30 
w/w, 63−200 μm particle size, from ICN). Melting points was determined in open capillaries on a 
Gallenkamp electrothermal apparatus. Purity of FA4 was established by high-performance liquid 
chromatography (HPLC) on an Agilent Infinity 1260 system equipped with diode array with a 
multiwavelenght UV/vis detector set at λ = 230 nm, 254 nm and 280 nm, through a Phenomenex 
Gemini RP-18 column (250 × 4.6 mm, 5 μm particle size, MeOH/H2O, 80:20 v/v at a flow rate of 
0.8 mL/min). 1H NMR spectra were recorded on a 500-vnmrs500 Agilent spectrometer (499.801 
MHz).  The following data were reported: chemical shift (δ) in parts per million (ppm), multiplicity 
(s = singlet, d = doublet, t = triplet, m = multiplet), integration, and coupling constant(s) in hertz. 
Mass spectrum was recorded on an Agilent 6890-5973 MSD gas chromatograph/mass spectrometer. 
High resolution mass spectroscopy (HRMS) was performed on a Agilent 6530 Accurate-Mass Q-




 A solution of 1 (0.297 g, 1.25 mmol) in CH3CN (10 mL) was added with K2CO3 (0.143 g, 1.04 
mmol) and 3H-spiro[isobenzofuran-1,4’-piperidine (0.196 g, 1.04 mmol). The resulting mixture 
was stirred under reflux overnight. The solvent was then removed under reduced pressure, and the 
residue was taken up with H2O and extracted with CH2Cl2 (3 × 7 mL). The collected organic layers 
were dried (Na2SO4) and evaporated under reduced pressure to afford a crude dark-red oil which 
was purified by column chromatography (AcOEt/MeOH 9:1) to give the title compound. GC/MS 
m/z 390 (M+, 10), 362 (15), 202 (100). The free base, dissolved in CH2Cl2 was transformed into the 
corresponding hydrochloride salt by addition of a solution of Et2O saturated with gaseous HCl. 
QTOF-HRMS for C24H26N2O3 (m/z): [M+H]+ calcd, 391.2022; found, 391.2021; [M+Na]+ calcd, 





dimethylhydrazinecarbothioamide hydrochloride. (FA4) 4,4-Dimethyl-3-thiosemicarbazide 
(0.017 g, 0.14 mmol) was added to a solution of 2 (0.055 g, 0.13 mmol) in hot ethanol and the 
mixture was refluxed for 5h. Upon cooling, a solid was obtained, filtered and washed with cold 
EtOH. Crystallization from EtOH (absolute) provided the title compound as yellow crystals (0.048 
g, 70% yield), mp = 203-204 °C; 1H NMR (500 MHz, CD3OD)  1.80-1.90 (m, 4H), 1.92-1.98 (m, 
2H), 2.25-2.35 (m, 2H), 3.15-3.25 (m, 2H), 3.40 (m, 4H),  3.48 (s, 6H), 3.93 (t, 2H, J = 6.4 Hz), 
5.10 (s, 2H), 7.14-7.22 (m, 3H), 7.27-7.36 (m, 3H), 7.43 (dt, 1H, J1 = 7.8 Hz, J2 = 1.5 Hz), 7.88 (br 
s, 1H, NH), 7.90-7.93 (m, 1H), 8.42 (s, 1H); QTOF-HRMS for C24H26N2O3 (m/z): [M+H]+ calcd, 









Reagents: A) 3H-spiro[isobenzofuran-1,4’-piperidine, K2CO3, CH3CN, ; B) 4,4-Dimethyl-3-





Table S1. Hematochemical parameters of treated animals  
 Ctrl FA4 low FA4 high GEM 
RBC (x 106/µl) 14.09±1.937 12.67±2.39 13.26 ±2.37 11.28±0.98 
Hb (g/dl) 13.98±1.18 12.87±3.43 12.83.2-83 11.03±1.94 
WBC (x 103/µl) 15.69±3.48 14.38±3.95 16.07±3.59 12.18±2.39 
PLT (x 103/µl) 984±302 983±283 1192±334 931±165 
LDH (U/l) 6594±1294 6453±604 7539±506 6704±832 
AST (U/l) 103±29 132±48 115±29 142±18 
ALT (U/l) 39±10 35±7 38±11 36±12 
AP (U/l) 107±14 117±32 162±45 134±43 
Creatinine (mg/l) 0.078±0.014 0.084±0.009 0.075±0.010 0.084±0.008 
CPK (U/l) 384±44 376±81 309±34 309±32 
 
Mice were treated as described in Figure 6. Blood was collected immediately after euthanasia and 
analyzed for red blood cells (RBC) count, hemoglobin (Hb), white blood cells (WBC) count, 
platelets (PLT) count, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (AP), creatinine, creatine phosphokinase (CPK). 
Data are presented as means ± SD.  
S6 
 
Figure S1. Density of sigma receptors in pancreatic cells by flow cytometry studies. Results are 
means ± SEM (n = 3), P < 0.05. 
 
A. Density of sigma-2 receptor in pancreatic cells 
 
 


































































Figure S2. Activation of caspase 3, 7, 9 by FA4 in pancreatic cell lines. Fluorimetric measure of 
caspase 3, 7, 9 in cells treated 2 h with a concentration of FA4 corresponding to its IC50 in each 
cell line (see Table 2). Results are means ± SEM (n = 3), P < 0.05. 
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Figure S3. Immunoblot of GRP78, ATF6, IRE1 and PERK in the indicated cell lines treated 2 h 
with a concentration of FA4 corresponding to its IC50 in each cell line (see Table 2). The image is 






Figure S4. Activities of pro-oxidant NADPH oxidase (A) and anti-oxidant superoxide dismutase 1 
(B), and catalase (C) enzymes in cells treated treated 2 h with 50 µM FA4. Results are means ± 
SEM (n = 3). 
A B C 






























































































































































































































































































































































Figure S5. FA4 efficacy against PANC-1 and MiaPaCa2 xenografts. FA4 in C57BL/6 mice 
bearing PANC-1 (panel A) or MiaPaCa2 (panel B) tumors, treated for 15 days as follows: 1) 
Vehicle group (black line, 100 µL saline solution); 2) FA4low group (red line, 750 nmoles FA4 in 
100 µL saline solution); 3) FA4high group (yellow line, 1500 nmoles FA4 in 100 µL saline solution); 
4) Gemcitabine group (green line, 20 mg/kg gemcitabine, twice a week). Animals were euthanized 
at day 18. Results are means ± SEM (n = 8). ***P<0.001: FA4-groups vs vehicle (day 18); #P<0.05, 
##P<0.001; FA4-groups vs gemcitabine (day 18). 
 
 
 
